Advertisement

Topics

FDA approves Idhifa for relapsed or refractory acute myeloid leukemia

09:35 EDT 2 Aug 2017 | CentreWatch

The FDA approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. “Idhifa […]

The post FDA approves Idhifa for relapsed or refractory acute myeloid leukemia appeared first on CenterWatch News Online.

Original Article: FDA approves Idhifa for relapsed or refractory acute myeloid leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA approves Idhifa for relapsed or refractory acute myeloid leukemia"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...